Helix BioPharma names CEO Thomas Mehrling to board, Janusz Grabski resigns

• Helix BioPharma announced board changes effective immediately.
• Janusz Grabski resigned as a director.
• CEO Thomas Mehrling, M.D., Ph.D., was appointed to the board under a nomination right tied to the 2025 Laevoroc acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Helix BioPharma Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608141700TNWSWRCACNPR_____1LpMF0453) on August 14, 2026, and is solely responsible for the information contained therein.